Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



14 day average Hospitalizations



7 day Average Deaths



Average test positivity past 7 days 5.0%, up 0.1% from last week
Cases are coming down from an early December peak
14 day average hospitalizations have plateaued and are starting to fall but are up about 2x the low in October
7 day average deaths remain at low levels.

- **Turnaround Time (for the week starting 01/29)**
- **91%** of PCR tests TAT< 1 day (2% decease from the previous week)
- **99%** of tests TAT < 2 days (1% increase from the previous week)
- *as of 02/07 -- Source: CalREDIE*

Feb 2 2023 with data as of Jan 31, 2023.
https://covid19.ca.gov/state-dashboard/



COVID-19 cases are falling in many countries around the world. In Japan, Hong Kong they are falling from a large peak. In the US cases are staying steady and relatively low. In Europe, there has been a slight rise in cases

Waning pop. immunity likely contributed to rise of cases in addition to new immune evasive variants

Highlighting the importance of booster vaccination.

Daily new confirmed COVID-19 deaths per million people

7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.

Our World in Data



Deaths are falling from a high level in Hong Kong and Japan. Deaths have increased in the US from 250per day to 600 per day

Variant Update: CDC Nowcast Estimate

Weighted and Nowcast Estimates in United States for Weeks of 10/30/2022 – 2/4/2023



Nowcast Estimates in United States for 1/29/2023 – 2/4/2023

USA

WHO label	Lineage #	US Class	%Total	95%PI	
Omicron	XBB.1.5	VOC	66.4%	59.8-72.5%	+10.5%
	BQ.1.1	VOC	19.9%	16.2-24.1%	-5.3%
	BQ.1	VOC	7.3%	5.8-9.0%	-2.9%
	XBB	VOC	2.3%	1.8-2.8%	-0.6%
	CH.1.1	VOC	1.6%	1.2-2.0%	-0.1%
	BN.1	VOC	1.1%	0.9-1.4%	-0.4%
	BA.5	VOC	0.5%	0.4-0.7%	-0.5%
	BF.7	VOC	0.5%	0.4-0.6%	-0.3%
	BA.5.2.6	VOC	0.2%	0.1-0.2%	-0.1%
	BA.2	VOC	0.1%	0.1-0.2%	-0.1%
	BF.11	VOC	0.1%	0.1-0.1%	0.0%
	BA.2.75	VOC	0.0%	0.0-0.1%	-0.1%
	BA.4.6	VOC	0.0%	0.0-0.0%	
	BA.2.75.2	VOC	0.0%	0.0-0.0%	
	B.1.1.529	VOC	0.0%	0.0-0.0%	
	BA.4	VOC	0.0%	0.0-0.0%	
	BA.1.1	VOC	0.0%	0.0-0.0%	
	BA.2.12.1	VOC	0.0%	0.0-0.0%	
Delta	B.1.617.2	VBM	0.0%	0.0-0.0%	
Other	Other*		0.1%	0.0-0.1%	

XBB.1.5

- XBB.1.5
- Fusion of BA.2.10.1.1 and BA.2.75.3.1.1.1
- Immune evasive, evades monoclonal antibodies
- Paxlovid still works
- Lineage has the greatest increase in growth in the US
- Highest number of cases in New York and East Coast 90% vs 35% for California

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid

- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date



Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date